Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 12/20 | 0.54 |
| ▸ | PPARA | Q07869 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979145 | 0.91 | KDM4E (0.65) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL4888378 | 0.88 | RAB9A (0.62) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL2980690 | 0.88 | KDM4E (0.58) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL28975550 | 0.87 | KDM4E (0.52) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL5022312 | 0.82 | KDM4E (0.61) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL3590990 | 0.82 | NPC1 (0.47) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL821405 | 0.82 | PPARG (0.59) | KDM4EPPARGPPARAHRH3HPGD | |
| SCHEMBL3530493 | 0.82 | RAB9A (0.53) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL7157388 | 0.82 | KDM4E (0.47) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL5204314 | 0.82 | KDM4E (0.54) | KDM4EPPARGPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1231482-C | Process for preparing thiazolidinedione derivatives and intermediates | HOFFMANN LA ROCHE (CH) | 2005-12-14 | — | — | CN | claimed |
| CN-1422267-A | Processes for the preparation of thiazolidinedione derivatives and intermediates | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | CN | claimed |
| EP-1401433-B1 | AZOLE ACID DERIVATIVES, ALONE OR IN COMBINATION, FOR TREATING DIABETES AND DYSLIPIDEMIAS; AND FOR TREATING MALIGNANT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7452907-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-7105556-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060189598-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2006-08-24 | — | — | US | disclosed |
| WO-2003040114-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092697-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-08 | — | — | US | disclosed |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-04-10 | — | — | US | disclosed |
| CN-1402712-A | Novel heterocyclic compounds and salts thereof and medicinal use of same | KYOTO PHARMA IND (JP) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002096357-A2 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1218361-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6414002-B1 | ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092697-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, GLP1R | KDM4E 1789/4885PPARG 155/4885PPARA 169/4885 |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | KDM4E 2366/4885PPARG 69/4885PPARA 48/4885 |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | KDM4E 2366/4885PPARG 69/4885PPARA 48/4885 |
| US-20060189598-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, GLP1R | KDM4E 1071/4885PPARG 170/4885PPARA 80/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | KDM4E 2164/4885PPARG 65/4885PPARA 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.